Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.05 (0.45%)
Data as of 02/22/17 10:51 a.m. ET
Refresh quote
Recent NewsMore >>
01/30/17Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
01/04/17Eiger Completes $25 Million Debt Financing with Oxford Finance
01/03/17Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
12/12/16Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
Upcoming EventsMore >>
Eiger BioPharmaceuticals at Cowen Healthcare Conference
LocationNY, NY
Eiger BioPharmaceuticals at EASL
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.